Randomized Trial of Anti-inflammatory Medications and Coronary Endothelial Dysfunction in Patients With Stable Coronary Disease.
AuthorHays, Allison G
Weiss, Robert G
JournalFrontiers in Cardiovascular Medicine
PublisherFrontiers Media S.A.
MetadataShow full item record
AbstractAims: Inflammation plays a critical role in the pathogenesis of coronary artery disease (CAD), however the impact of anti-inflammatory therapies to reduce those processes which promote atherosclerosis in CAD patients is unknown. We aimed to test the hypothesis that anti-inflammatory approaches improve impaired coronary endothelial function (CEF), a driver of coronary atherosclerosis, in stable CAD patients. Methods and Results: We performed a single-center, randomized, placebo-controlled, double-blinded trial to assess whether low dose methotrexate (MTX), low dose colchicine (LDC), and/or their combination (MTX+LDC), improves CEF using non-invasive MRI measures in patients with stable CAD (N = 94). The primary endpoint was the MRI-detected change in coronary cross-sectional area from rest to isometric handgrip exercise (IHE), a predominantly nitric oxide-dependent endothelial dependent stressor. Coronary and systemic endothelial endpoints, and serum inflammatory markers, were collected at baseline, 8 and 24 weeks. Anti-inflammatory study drugs were well-tolerated. There were no significant differences in any of the CEF parameters among the four groups (MTX, LDC, MTX+LDC, placebo) at 8 or 24 weeks. Serum markers of inflammation and systemic endothelial function measures were also not significantly different among the groups. Conclusion: This is the first study to examine the effects of the anti-inflammatory approaches using MTX, LDC, and/or the combination in stable CAD patients on CEF, a marker of vascular health and the primary endpoint of the study. Although these anti-inflammatory approaches were relatively well-tolerated, they did not improve coronary endothelial function in patients with stable CAD. Clinical Trial Registration: www.clinicaltrials.gov, identifier: NCT02366091.
Rights/TermsCopyright © 2021 Hays, Schär, Bonanno, Lai, Meyer, Afework, Steinberg, Stradley, Gerstenblith and Weiss.
Keywordcoronary artery disease
coronary endothelial function
flow mediated dilatation
magnetic resonance imaging
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/17057
- A randomized, placebo-controlled, double-blinded clinical trial of colchicine to improve vascular health in people living with HIV.
- Authors: Hays AG, Schär M, Barditch-Crovo P, Bagchi S, Bonanno G, Meyer J, Afework Y, Streeb V, Stradley S, Kelly S, Anders NM, Margolick JB, Lai S, Gerstenblith G, Weiss RG
- Issue date: 2021 Jun 1
- The influence of febuxostat on coronary artery endothelial dysfunction in patients with coronary artery disease: A phase 4 randomized, placebo-controlled, double-blind, crossover trial.
- Authors: Hays AG, Iantorno M, Schär M, Lai S, Czarny M, Breton E, Palmer RN, Whelton A, Weiss RG, Gerstenblith G
- Issue date: 2018 Mar
- Coronary vasomotor responses to isometric handgrip exercise are primarily mediated by nitric oxide: a noninvasive MRI test of coronary endothelial function.
- Authors: Hays AG, Iantorno M, Soleimanifard S, Steinberg A, Schär M, Gerstenblith G, Stuber M, Weiss RG
- Issue date: 2015 Jun 1
- Regional coronary endothelial dysfunction is related to the degree of local epicardial fat in people with HIV.
- Authors: Iantorno M, Soleimanifard S, Schär M, Brown TT, Bonanno G, Barditch-Crovo P, Mathews L, Lai S, Gerstenblith G, Weiss RG, Hays AG
- Issue date: 2018 Nov
- Local coronary wall eccentricity and endothelial function are closely related in patients with atherosclerotic coronary artery disease.
- Authors: Hays AG, Iantorno M, Schär M, Mukherjee M, Stuber M, Gerstenblith G, Weiss RG
- Issue date: 2017 Jul 6